[
  {
    "ts": "2025-09-24T16:49:47+00:00",
    "headline": "Biogen’s high-dose Spinraza turned down by FDA due to CMC troubles",
    "summary": "Biogen is one in a list of companies that have recently faced rejections due to CMC issues.",
    "url": "https://www.pharmaceutical-technology.com/news/biogen-spinraza-high-dose-fda-rejection/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "ac99487a-6076-3b36-a38c-7a8a96f3fd07",
      "content": {
        "id": "ac99487a-6076-3b36-a38c-7a8a96f3fd07",
        "contentType": "STORY",
        "title": "Biogen’s high-dose Spinraza turned down by FDA due to CMC troubles",
        "description": "",
        "summary": "Biogen is one in a list of companies that have recently faced rejections due to CMC issues.",
        "pubDate": "2025-09-24T16:49:47Z",
        "displayTime": "2025-09-24T16:49:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/ffb0623359925ac2464109ea06abdb82",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "The FDA has declined to approve the high dose of Biogen's Spinraza due to CMC issues with the spinal muscular atrophy (SMA) treatment's supplemental new drug application (sNDA). Image credit: Sergei Elagin via ShutterStock.com.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/km7WYaC4p4YmUowDxyU4Pg--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/ffb0623359925ac2464109ea06abdb82.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/avn2.VZ8f9pKS3AjGiTl2Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/ffb0623359925ac2464109ea06abdb82.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/biogen-spinraza-high-dose-fda-rejection/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-high-dose-spinraza-turned-164947390.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-24T16:41:00+00:00",
    "headline": "BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL",
    "summary": "FDA issues CRL to Biogen's regulatory filing seeking approval for a higher dose of SMA drug, Spinraza. The company plans prompt resubmission.",
    "url": "https://finance.yahoo.com/news/biibs-snda-higher-dose-sma-164100232.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "0d39998d-80e8-3d80-9575-602563f08bc7",
      "content": {
        "id": "0d39998d-80e8-3d80-9575-602563f08bc7",
        "contentType": "STORY",
        "title": "BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL",
        "description": "",
        "summary": "FDA issues CRL to Biogen's regulatory filing seeking approval for a higher dose of SMA drug, Spinraza. The company plans prompt resubmission.",
        "pubDate": "2025-09-24T16:41:00Z",
        "displayTime": "2025-09-24T16:41:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/7d0183f93b51892d562cc8047433f507",
          "originalWidth": 620,
          "originalHeight": 496,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FrubqPEJ5SQTnAyfM_xUDw--~B/aD00OTY7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7d0183f93b51892d562cc8047433f507.cf.webp",
              "width": 620,
              "height": 496,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CQa3fKpJjXlLKWCIXJxJDg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7d0183f93b51892d562cc8047433f507.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biibs-snda-higher-dose-sma-164100232.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biibs-snda-higher-dose-sma-164100232.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVS"
            },
            {
              "symbol": "NVSEF"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "RHHBY"
            },
            {
              "symbol": "RHHVF"
            },
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-24T11:30:00+00:00",
    "headline": "LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia",
    "summary": "TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Therapeutic Goods Administration (TGA) of Australia has approved the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (brand name, generic name: lecanemab) for mild cognitive impairment (MCI",
    "url": "https://finance.yahoo.com/news/leqembi-lecanemab-approved-treatment-alzheimer-113000671.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "faeb5317-8b97-3d18-8609-af9ff4453d78",
      "content": {
        "id": "faeb5317-8b97-3d18-8609-af9ff4453d78",
        "contentType": "STORY",
        "title": "LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia",
        "description": "",
        "summary": "TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Therapeutic Goods Administration (TGA) of Australia has approved the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (brand name, generic name: lecanemab) for mild cognitive impairment (MCI",
        "pubDate": "2025-09-24T11:30:00Z",
        "displayTime": "2025-09-24T11:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d",
          "originalWidth": 865,
          "originalHeight": 290,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IDD9DHtEaM8wc.4J0e2kkA--~B/aD0yOTA7dz04NjU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 865,
              "height": 290,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iODOrgJZ_MV95T9B.jt0vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/leqembi-lecanemab-approved-treatment-alzheimer-113000671.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/leqembi-lecanemab-approved-treatment-alzheimer-113000671.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]